Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. (NCT06590857)

🧪 Interventions in This Study

• RYZ101 (DRUG)
• Standard of Care Endocrine Therapy (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• Research Facility — Phoenix, Arizona
• Research Facility — Irvine, California
• Research Facility — San Diego, California
• Research Facility — Santa Monica, California
• Research Facility — Longmont, Colorado
• Research Facility — Jacksonville, Florida
• Research Facility — Atlanta, Georgia
• Research Facility — Indianapolis, Indiana
• Research Facility — Boston, Massachusetts
• Research Facility — Detroit, Michigan
• Research Facility — Rochester, Minnesota
• Research Facility — St Louis, Missouri
• Research Facility — Omaha, Nebraska
• Research Facility — Albuquerque, New Mexico
• Research Facility — Buffalo, New York
• Research Facility — New York, New York
• Research Facility — New York, New York
• Research Facility — Cleveland, Ohio
• Research Facility — Philadelphia, Pennsylvania
• Research Facility — Pittsburgh, Pennsylvania
• Research Facility — Dallas, Texas
• Research Facility — Houston, Texas
• Research Facility — Salt Lake City, Utah
• Research Facility — Norfolk, Virginia
• Research Facility — Seattle, Washington

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Breast Cancer

• Assessing the Time Demands of Cancer — Birmingham, Alabama
• Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — Birmingham, Alabama
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer — Commack, New York
• Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Washington D.C., District of Columbia
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer — Tucson, Arizona
• Roll-over Study to Allow Continued Access to Ribociclib — Chandler, Arizona

Explore by condition: All Metastatic Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.